EXTRACELLULAR VESICLES AND THEIR ROLE IN PATIENTS WITH MULTIPLE MYELOMA

1ST JULY 2021

FREE REGISTRATION
SOHOITALY.IT

10,5 CME/ECM FOR: PHYSICIANS, BIOLOGISTS, BIOMEDICAL LABORATORY TECHNICIANS, NURSES

@SOHOITALY

INFO@PROEVENTI.IT www.PROEVENTI.IT
In the past decade, there have been major advances in the treatment of the blood cancer Multiple Myeloma (MM). The introduction of novel agents such as immune-modifying agents (IMIDs), proteasome inhibitors, monoclonal antibodies, with or without stem cell transplantation, has resulted in significantly improved patient survival. Meanwhile, the increased understanding of MM tumor biology has provided a rationale for new combinations of drugs and risk-adapted and individualized treatments to further improve patient management.

Extracellular vesicles (EVs) are cell-derived membranous particles that mediate cell-to-cell communication by transferring proteins, lipids and nucleic acids locally and through systemic circulation. EVs are active regulators in the cross-talk between MM tumour cells and bone marrow microenvironment, with the capacity to alter angiogenesis, osteoclast differentiation and immunosuppression, promoting tumour progression and drug resistance. Circulating EVs containing tumour-specific molecular signatures (oncoproteins, RNAs, DNA fragments) have potential clinical utility as next-generation liquid biopsy biomarkers in cancer diagnosis and management, with the potential to characterise both spatial heterogeneity and clonal evolution thus informing new modalities for diagnosis, risk stratification, monitoring and therapeutic intervention in MM. However, the nano-scale nature of EVs and the complexity of biofluids present challenges that need to be addressed before the potential of EVs as biomarkers and therapeutic targets can be achieved.

The Italian Society of Hematologic Oncology (SOHO Italy) was established as a non-profit organization in 2019 to promote worldwide research (education, prevention, preclinical and clinical studies and patient care) of hematologic malignancies and related disorders. In this scenario, SOHO Italy together with Australian colleagues aim to bring together international experts to discuss the latest advances in the pathophysiology and therapy of MM and to better understand the role of EVs in patients with MM.
07.45 WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
07.50 OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS
H. EINSELE A. SPENCER G. MARTINELLI
08.00 THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J. L. HAROUSSEAU
08.20 ROLE OF MICROENVIRONMENT IN MM A. VACCA
08.40 IMMUNE SYSTEM IN MM P. NERI
09.00 VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU
09.20 ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A. G. SOLIMANDO
09.30 LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES
M. BEBAWY A. VACCA D. W. GREENING
10.20 EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER
10.40 EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI
11.00 EVS AS CANCER DIAGNOSTICS A. MÜLLER
11.20 EV Bystander Signaling and Cancer Resistance P. SAMUEL
11.40 TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG
12.00 ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV-BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI
12.10 STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA
K. C. ANDERSON C. CERCHIONE M. V. MATEOS
12.55 HOW I MANAGE FRONTLINE MM M. V. MATEOS
13.15 HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE
13.35 BIOLOGICALLY BASED THERAPIES FOR MM K. C. ANDERSON
13.55 NEW TREATMENT AVENUES IN MM H. C. LEE
14.15 MANAGING INFECTIONS IN MM R. RIA
14.35 ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA
A. REALE G. SIMONETTI B. SUNG
14.55 EVS IN MM BONE DISEASE K. VANDERKERKEN
15.15 EVS IN MM PROGRESSION A. ROCCARO
15.35 MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA
15.55 MM- SMALL EVS, OMICS, PLASMA A. REALE
16.15 ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO
16.25 LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING
16.55 CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

Colgene | Bristol Myers Squibb Company | gsk | Janssen Oncology | Karyopharm Therapeutics | Takeda
11.45PM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
11.50PM (30TH JUNE) OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS
H. EINSELE A. SPENCER G. MARTINELLI
12.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU
12.20AM ROLE OF MICROENVIRONMENT IN MM A. VACCA
12.40AM IMMUNE SYSTEM IN MM P. NERI
01.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU
01.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO
01.30AM LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES
M. BEBAWY A. VACCA D. W. GREENING
02.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER
02.40AM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI
03.00AM EVS AS CANCER DIAGNOSTICS A. MÖLLER
03.20AM EV Bystander Signaling and Cancer Resistance P. SAMUEL
03.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG
04.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV-BOUND THERAPEUTIC ANTI-CDSB ANTIBODIES IN MULTIPLE MYELOMA A. FAINI
04.10AM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA
K.C. ANDERSON C. CERCHIONE M.V. MATEOS
04.55AM HOW I MANAGE FRONTLINE MM M. V. MATEOS
05.15AM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE
05.35AM BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON
05.55AM NEW TREATMENT AVENUES IN MM H. C. LEE
06.15AM MANAGING INFECTIONS IN MM R. RIA
06.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA
A. REALE G. SIMONETTI B. SUNG
06.55AM EVS IN MM BONE DISEASE K. VANDERKERKEN
07.15AM EVS IN MM PROGRESSION A. ROCCARO
07.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA
07.55AM MM SMALL EVS, OMICS, PLASMA A. REALE
08.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCES MANAGEMENT E. IACCINO
08.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING
08.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM
12.45AM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
12.50AM OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS
H. EINSELE A. SPENCER G. MARTINELLI
01.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU
01.20AM ROLE OF MICROENVIRONMENT IN MM A. VACCA
01.40AM IMMUNE SYSTEM IN MM P. NERI
02.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU
02.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIogenesis AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO
02.30AM LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES
M. BEBAWY A. VACCA D. W. GREENING
03.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER
03.40AM EXTRACELLULAR VESICLES IN CANCER - IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI
04.00AM EVs AS CANCER DIAGNOSTICS A. MÖLLER
04.20AM EV BYSTANDER SIGNALING AND CANCER RESISTANCE P. SAMUEL
04.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVs B. SUNG
05.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV-BOUND THERAPEUTIC ANTI-CO38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI
05.10AM STUDENT/ECR NETWORK ON EVs (SNEV), OVERVIEW A. NASIRI-KENARI

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA
K.C. ANDERSON C. CERCHIONE M.V. MATEOS
05.55AM HOW I MANAGE FRONTLINE MM M. V. MATEOS
06.15AM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE
06.35AM BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON
06.55AM NEW TREATMENT AVENUES IN MM H.C. LEE
07.15AM MANAGING INFECTIONS IN MM R. RIA
07.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA
A. REALE G. SIMONETTI B. SUNG
07.55AM EVs IN MM BONE DISEASE K. VANDERKERKEN
08.15AM EVs IN MM PROGRESSION A. ROCCARO
08.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIogenesis VIA SMALL EVs RELEASE I. SALTARELLA
08.55AM MM-SMALL EVs, OMICS, PLASMA A. REALE
09.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCES MANAGEMENT E. IACCINO
09.25AM LECTURE PROTEOMIC INSIGHTS IN EVs: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING
09.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM
01.45AM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
01.50AM OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS
H. EINSELE A. SPENCER G. MARTINELLI
02.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU
02.20AM ROLE OF MICROENVIRONMENT IN MM A. VACCA
02.40AM IMMUNE SYSTEM IN MM P. NERI
03.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU
03.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO
03.30AM LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES
M. BEBAWY A. VACCA D. W. GREENING
04.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER
04.40AM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI
05.00AM EVS AS CANCER DIAGNOSTICS A. MÖLLER
05.20AM EV Bystander SIGNALING AND CANCER RESISTANCE P. SAMUEL
05.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG
06.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV-BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI
06. 10AM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA
K.C. ANDERSON C. CERCHIONE M.V. MATEOS
06.55AM HOW I MANAGE FRONTLINE MM M. V. MATEOS
07.15AM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE
07.35AM BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON
07.55AM NEW TREATMENT AVENUES IN MM H.C. LEE
08.15AM MANAGING INFECTIONS IN MM R. RIA
08.35AM ORAL COMMUNICATION BONE AND EXTRA-MEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA
A. REALE G. SIMONETTI B. SUNG
08.55AM EVS IN MM BONE DISEASE K. VANDERKERKEN
09.15AM EVS IN MM PROGRESSION A. ROCCARO
09.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA
09.55AM MM-SMALL EVS, OMICS, PLASMA A. REALE
10.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO
10.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING
10.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>03.45PM</td>
<td>WHAT IS SOHO ITALY</td>
<td>C. Cerchione, G. Martinelli</td>
</tr>
<tr>
<td>03.50PM</td>
<td>OPENING REMARKS</td>
<td>C. Cerchione, D. W. Greening, G. Martinelli, A. Reale, A. Spencer, A. Vacca</td>
</tr>
<tr>
<td>03.55PM</td>
<td>SESSION 1 - THE MULTIPLE MYELOMAS</td>
<td>H. Einsele, A. Spencer, G. Martinelli</td>
</tr>
<tr>
<td>04.00PM</td>
<td>THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION</td>
<td>J.L. Harousseau</td>
</tr>
<tr>
<td>04.20PM</td>
<td>ROLE OF MICROENVIRONMENT IN MM</td>
<td>A. Vacca</td>
</tr>
<tr>
<td>04.40PM</td>
<td>IMMUNE SYSTEM IN MM</td>
<td>P. Neri</td>
</tr>
<tr>
<td>05.00PM</td>
<td>VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM</td>
<td>I. Savvidou</td>
</tr>
<tr>
<td>05.20PM</td>
<td>ORAL COMMUNICATION</td>
<td>A.G. Solimando</td>
</tr>
<tr>
<td>05.30PM</td>
<td>LECTURE LIQUID BIOPSY IN MM</td>
<td>A. Spencer</td>
</tr>
<tr>
<td>06.20PM</td>
<td>SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES</td>
<td>M. Bebawy, A. Vacca, D. W. Greening</td>
</tr>
<tr>
<td>06.20PM</td>
<td>EXTRACELLULAR VESICLES - OVERVIEW, UPDATE</td>
<td>K. Witwer</td>
</tr>
<tr>
<td>06.40PM</td>
<td>EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE</td>
<td>A. Rai</td>
</tr>
<tr>
<td>07.00PM</td>
<td>EVS AS CANCER DIAGNOSTICS</td>
<td>A. Müller</td>
</tr>
<tr>
<td>07.20PM</td>
<td>EV Bystander Signaling and Cancer Resistance</td>
<td>P. Samuel</td>
</tr>
<tr>
<td>07.40PM</td>
<td>TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS</td>
<td>B. Sung</td>
</tr>
<tr>
<td>08.00PM</td>
<td>ORAL COMMUNICATION</td>
<td>K. Vanderkerken</td>
</tr>
<tr>
<td>08.10PM</td>
<td>STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW</td>
<td>A. Nasiri Kenari</td>
</tr>
<tr>
<td>08.20PM</td>
<td>SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA</td>
<td>K.C. Anderson, C. Cerchione, M.V. Mateos</td>
</tr>
<tr>
<td>08.55PM</td>
<td>HOW I MANAGE FRONTLINE MM</td>
<td>M. V. Mateos</td>
</tr>
<tr>
<td>09.15PM</td>
<td>HOW I MANAGE RELAPSED/REFRACTORY MM</td>
<td>C. Cerchione</td>
</tr>
<tr>
<td>09.35PM</td>
<td>BIOLOGICALLY BASED THERAPIES FOR MM</td>
<td>K.C. Anderson</td>
</tr>
<tr>
<td>09.55PM</td>
<td>NEW TREATMENT AVENUES IN MM</td>
<td>H.C. Lee</td>
</tr>
<tr>
<td>10.15PM</td>
<td>MANAGING INFECTIONS IN MM</td>
<td>R. Ria</td>
</tr>
<tr>
<td>10.35PM</td>
<td>ORAL COMMUNICATION</td>
<td>Z. Kozich</td>
</tr>
<tr>
<td>10.55PM</td>
<td>EVs in MM bone disease</td>
<td>K. Vanderkerken</td>
</tr>
<tr>
<td>11.15PM</td>
<td>EVs in MM progression</td>
<td>A. Roccaro</td>
</tr>
<tr>
<td>11.35PM</td>
<td>MM fibroblasts enhance bone marrow angiogenesis via small EVs release</td>
<td>I. Saltarella</td>
</tr>
<tr>
<td>11.55PM</td>
<td>MM-SMALL EVS, OMICS, PLASMA</td>
<td>A. Reale</td>
</tr>
<tr>
<td>12.15AM</td>
<td>ORAL COMMUNICATION</td>
<td>E. Iaccino</td>
</tr>
<tr>
<td>12.25AM</td>
<td>LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY</td>
<td>D. W. Greening</td>
</tr>
<tr>
<td>12.55AM</td>
<td>CLOSING REMARKS</td>
<td>C. Cerchione, G. Martinelli, A. Vacca</td>
</tr>
</tbody>
</table>

**Supported by an Unrestricted Educational Grant from**

Colgene | Bristol Myers Squibb Company | gsk | Janssen Oncology | Karyopharm Therapeutics | Takeda
05.45PM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
06.00PM OPENING REMARKS C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA
06.00PM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU
06.20PM ROLE OF MICROENVIRONMENT IN MM A. VACCA
06.40PM IMMUNE SYSTEM IN MM P. NERI
07.00PM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU
07.20PM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO
07.30PM LECTURE LIQUID BIOPSY IN MM A. SPENCER
10.55PM HOW I MANAGE FRONTLINE MM M. V. MATEOS
11.15PM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE
11.35PM BIOLGICALLY BASED THERAPIES FOR MM K.C. ANDERSON
11.55PM NEW TREATMENT AVENUES IN MM H.C. LEE
12.15AM MANAGING INFECTIONS IN MM R. RIA
12.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES
M. BEBAWY A. VACCA D. W. GREENING
08.20PM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER
08.40PM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI
09.00PM EVS AS CANCER DIAGNOSTICS A. MÖLLER
09.20PM EV Bystander Signaling and Cancer Resistance P. SAMUEL
09.40PM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG
10.00PM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV-BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI
10.10PM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI
12.55AM EVS IN MM BONE DISEASE K. VANDERKERKEN
01.15AM EVS IN MM PROGRESSION A. ROCCARO
01.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA
01.55AM MM-SMALL EVS, OMICS, PLASMA A. REALE
02.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO
02.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING
02.55AM ORAL COMMUNICATION CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA
A. REALE G. SIMONETTI B. SUNG
10.55AM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI
12.55AM EVS IN MM BONE DISEASE K. VANDERKERKEN
01.15AM EVS IN MM PROGRESSION A. ROCCARO
01.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA
01.55AM MM-SMALL EVS, OMICS, PLASMA A. REALE
02.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO
02.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING
02.55AM ORAL COMMUNICATION CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM